市場調査レポート
商品コード
1279707
細胞表面マーカー検出の世界市場- 2023-2030年Global Cell Surface Markers Detection Market - 2023-2030 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
細胞表面マーカー検出の世界市場- 2023-2030年 |
出版日: 2023年05月26日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 約2営業日
|
細胞表面マーカー検出の世界市場規模は、2022年に49億7,650万米ドルに達し、2030年には最大95億2,260万米ドルに達することで有利な成長が予測されます。同市場は予測期間(2023年~2030年)に8.7%のCAGRを記録しています。
細胞表面マーカー検出は、特定の抗体が結合した特定の膜タンパク質(すなわち表面マーカー)を用いて、フローサイトメトリーで蛍光細胞を分離するために使用されます。蛍光活性化セルソーティング(FACS)分析によるヒト造血幹細胞の同定と精製に用いられる細胞表面マーカー検出には、多くの分化クラスター(CD)マーカーが組み込まれています。最も原始的なヒト造血幹細胞はCD34+CD90+と同定され、他のグループはCD34+CD38と同定しています。
CD45RAの発現がない場合も、上記のマーカーと組み合わせて、原始的な造血幹細胞の同定に用いられています。ヒト多能性前駆細胞はLinCD34+CD38CD90c-kitloflt3loCD133+CD45RAとして同定されます。CMP(赤血球、顆粒球、巨核球、マクロファージ)およびCLP(B細胞、T細胞、NK細胞)の分化した子孫は、FACS分析において、系統特異的マーカーの存在によって識別されます。例えば、Bリンパ球はCD45+CD20+CD24+、Tリンパ球はCD45+CD3+、巨核球はCD42b+、顆粒球はCD45+CD15+CD24+CD114+CD182+、マクロファージはCD45+CD68+です。
プレシジョンメディシンは、特定の患者集団の分子的・環境的要因に沿った医療を目指す概念です。バイオマーカーを活用した治療は、精密医療の重要なサブディシプリンであり、 促進要因変異、タンパク質発現、mRNA、MSI(マイクロサテライト不安定性)、腫瘍変異負荷(TMB)、エピジェネティックバイオマーカーなどが含まれます。バイオマーカーは、DNA、mRNA、タンパク質をベースとし、 促進要因変異、タンパク質発現、mRNA、MSI、腫瘍変異負荷(TMB)、エピジェネティックバイオマーカーが含まれます。
フローサイトメトリー、免疫組織化学(IHC)、次世代シーケンシング(RNAシーケンス)は、集団の細胞表面マーカー検出を同定または診断するために用いられる方法です。RNA-Seqは、次世代シーケンサーを使用してcDNAの配列を並行して決定し、RNA断片に見られる塩基対の配列を示す大量のデータを作成します。細胞表面マーカー検出のための診断の増加と迅速化が市場を牽引しています。
フローサイトメトリーのような高価な装置とその複雑さが、市場の成長を妨げる主な理由です。フローサイトメトリーのコストは地域によって異なるが、非常に高価です。例えば、ソニーのように10万円以下のフローサイトメトリー機器を作り始めているメーカーもありますが、それでも1台で10万円から50万円はかかる可能性があります。つまり、これが細胞表面マーカー検出の市場成長を阻害する主な要因となっています。
細胞表面マーカー検出は細胞膜に付着し、細胞間シグナル伝達に重要な役割を果たすため、COVID-19の大流行は市場に大きな影響を与えると予想されます。COVID-19患者と健常対照者の単球における細胞表面マーカー検出を比較するなど、COVID-19抗体と細胞表面マーカー検出との相互作用を考慮した調査プロジェクトが行われています。
この研究では、COVID-19患者さんで真菌の共同感染率が高いことがわかり、病気の理解を深め、治療法を見つけるための革新的な方法につながっています。また、細胞表面マーカー検出は、パンデミック時のCOVID-19の効果を研究するために使用されています。
ロシア・ウクライナ紛争は、東欧、欧州連合、東・中央アジア、米国を中心に、世界的に悪影響を及ぼしています。ウクライナへの悪影響、ロシアへの長期的な影響が予想されます。戦争により、需給バランス、価格変動、輸出入、取引に影響があり、細胞表面マーカー検出市場に短期的な影響が見られることがあります。
The global cell surface markers detection market size reached US$ 4,976.5 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 9,522.6 million by 2030. The market is exhibiting at a CAGR of 8.7% during the forecast period (2023-2030).
The cell surface marker is used to separate fluorescent cells by flow cytometry by using a specific membrane protein (i.e., surface marker) bound by a specific antibody. The cell surface markers used for the identification and purification of human HSCs by fluorescence-activated cell sorting (FACS) analysis incorporate a number of clusters of differentiation (CD) markers. The most primitive human HSC is identified as CD34+CD90+, while other groups have identified it as CD34+CD38.
Absent expression of CD45RA has also been used in combination with the above markers for the identification of primitive HSCs. Human multipotent progenitor cells are identified as LinCD34+CD38CD90c-kitloflt3loCD133+CD45RA. Differentiated progeny of CMP (erythrocytes, granulocytes, megakaryocytes, and macrophages) and CLP (B cell, T cell, NK cell) is identified by the presence of lineage-specific markers in FACS analysis. For Instance, B- lymphocytes are CD45+CD20+CD24+, T-lymphocytes are CD45+CD3+, megakaryocytes are CD42b+, granulocytes are CD45+CD15+CD24+CD114+CD182+, and macrophages are CD45+CD68+.
Precision medicine is a concept that aims to align medical care with the molecular and environmental factors of certain patient groups. Biomarker-supported therapy is an essential sub-discipline of precision medicine, which includes driver mutations, protein expression, mRNA, MSI (microsatellite instability), tumor mutational burden (TMB), and epigenetic biomarkers. Biomarkers are DNA-, mRNA-, or protein-based and include driver mutations, protein expression, mRNA, MSI, tumor mutational burden (TMB), and epigenetic biomarkers.
Flow Cytometry, Immunohistochemistry (IHC), and Next Generation Sequencing (RNA Sequencing) are methods used to identify or diagnose the cell surface markers in a population. RNA-Seq uses next-generation sequencing to sequence cDNA in parallel to create large amounts of data showing the sequence of base pairs found in RNA fragments. Increased and quick diagnostics for cell surface markers detection drives the market.
Expensive instruments like flow cytometry and their complexity are the main reasons to hamper the market growth. The cost of the flow cytometry varies from region but it is very expensive. For instance, some manufacturers, such as Sony, are beginning to build flow cytometer instruments that cost under $100,000, but it's still possible to spend anywhere from $100,000 to $500,000 for a single unit. So, this is the main factor hindering the market growth of cell surface markers detection.
The COVID-19 pandemic is expected to have a significant impact on the market, as cell surface markers are attached to the cell membrane and play a crucial role in intercellular signaling. Research projects are being conducted that involve the interaction of COVID-19 antibodies with cell surface markers, such as comparing the cell surface marker expression on monocytes of COVID-19 patients with healthy controls.
This study found an increased rate of fungal co-infections in COVID-19 patients, leading to a better understanding of the disease and innovative ways to find a cure. The cell surface markers are also used to study the effect of COVID-19 during the pandemic.
The Russia-Ukraine Conflict has caused negative impacts globally, particularly in Eastern Europe, the European Union, Eastern & Central Asia, and the United States. It is expected to have an adverse impact on Ukraine and long-term effects on Russia. Due to the wars, implications for demand-supply balances, pricing variants, import/export and trading, short-term impact can be seen in the cell surface markers detection market.
The global cell surface markers detection market is segmented by product and by application.
Flow cytometry is a technique used to detect the presence of cell types within a population by passing single cells through a highly focused laser. Antibodies specific to cell surface markers of interest are added to a sample and allowed to bind to the cells. These antibodies are conjugated to fluorochromes which emit light at various wavelengths. The population of cells is then passed through a laser, exciting the fluorochromes and capturing the light emitted.
The cells are then sorted into subpopulations based on the markers present through a series of histograms and dot plots called a gating strategy. Flow cytometry allows for multiple cell surface markers on a cell to be detected, but nonspecific binding and spectral overlap can become a limitation. Flow cytometry also does not allow for the spatial aspect of a sample to be analyzed as the cells are suspended and fed through the laser one at a time. The flow cytometry segment holds about 37.6% of the total cell surface markers market in the forecast period owing to its multiple advantages in analysing cell surface markers.
The North America region holds the largest share of the global cell surface markers detection market accounting for approximately 39.7% in the forecast period owing to the strong presence of the clinical research sector in the region's developed economies. The presence of leading players in the medical research sector has elevated the medical research sector in North America and the strong presence of cellular researchers in North America is likely to be a major driver for the market. The increased awareness about the cell surface markers is more likely to drive the market in North America.
The major global players in the market include: BD, Nihon Kohden Corporation, Sysmex Corporation, Thermo Fisher Scientific, Grifols, Bio Rad Laboratories Inc., Agilent Technologies Inc., Nexcelom Bioscience LLC, Beckman Coulter Inc., IVD Medical Holding Limited (Immucor Inc.), and Luminex Corporation.
The global Cell Surface Markers Detection Market report would provide approximately 54 tables, 46 figures, and 195 Pages.
LIST NOT EXHAUSTIVE